Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Francesco Marchesi, Jon Salmanton-Garc ía, Caterina Buquicchio, Federico Itri, Caroline Besson, Julio Dávila-Valls, Sonia Martín-Pérez, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Mariarita Sciume, Jorge Labrador, Raul Co Tags: Correspondence Source Type: research